Key facts
- Eli Lilly shares rose 4% premarket following positive late-stage trial results for its obesity drug, retatrutide.
- The 4mg dose of retatrutide demonstrated approximately 19% weight loss, comparable to current blockbuster therapies.
Eli Lilly shares surged 4% premarket after presenting compelling late-stage trial data for its obesity drug, retatrutide. Analysts expect the drug to solidify Lilly's lead in the weight-loss market, with a 4mg dose showing approximately 19% weight loss.
The positive trial results for Eli Lilly's retatrutide are significant as they suggest the drug could offer comparable efficacy to current market leaders with manageable side effects, potentially extending Lilly's dominance in the lucrative and expanding obesity treatment market.
Eli Lilly shares jumped 4% in premarket trading on Monday after the company presented compelling new data for its next-generation obesity drug, retatrutide, at the American Diabetes Association meeting. Investors and analysts anticipate the drug will further solidify Lilly's leading position in the rapidly growing weight-loss market.
The most encouraging results came from the 4 mg dose of retatrutide, which achieved approximately 19% weight loss, a figure comparable to the highest dose of current market leader Zepbound. Tolerability was generally consistent, with similar rates of treatment discontinuation and relatively low instances of vomiting, although side effects did increase at higher doses.
Analysts from Citi noted that the efficacy of the 4mg dose is strong enough to warrant consideration for first-line treatment, positioning it as a subsequent option for patients who have already utilized Lilly's tirzepatide. The competitive landscape in the obesity market is increasingly focused on balancing efficacy with fewer side effects and simpler administration.
Eli Lilly's stock has gained 5.2% year-to-date, following a substantial rally in the previous year. In contrast, its primary competitor, Novo Nordisk, has experienced a roughly 15% decline year-to-date. J.P. Morgan analyst Chris Schott stated that Lilly possesses the necessary components to elevate the standard of care in obesity treatment and extend its long-term leadership in the over $200 billion incretin/obesity market.
Lilly also shared additional data on other candidates, including an approved weight-loss pill and another experimental injectable, eloralintide. RBC Capital Markets analyst Trung Huynh commented that the breadth of Lilly's obesity pipeline underscores its growing leadership and widening gap with competitors.